Coronavirus Update:What patients and families need to know
Pediatric Psychopharmacology Team
The Pediatric Psychopharmacology Team from the Division of Psychology and Behavioral Health is funded by both industry and the NIH to investigate new therapies for psychiatric and behavioral disorders in children ages 5 to 17 years. The Team collaborates with investigators across the U.S. and around the world to identify best practices in testing psychotropic medications for both safety and efficacy. Areas of interest span the psychiatric field from autism to schizophrenia. In addition, the team is a training resource for other investigators on best practices for evaluating study subjects, consenting practices and retention of enrolled participants. Trials with frequent pharmacokinetic sampling often incorporate the expertise of the CTSI-CN nursing and ancillary staff.
Recent studies have included a phase I trial of a novel antidepressant where Children’s National Hospital was the first center to establish dosing in a pediatric cohort. This agent is currently undergoing phase III study at multiple sites including Children’s National. A second national trial is evaluating add-on treatment for aggression in ADHD, using a handheld device to record aggressive behavior which is then loaded directly into the study database, optimizing data accuracy and eliminating parental recall bias.
Since its inception, the Psychopharmacology Trials Team has conducted over 75 registration trials leading to the FDA approval of multiple medications for:
- Attention deficit hyperactivity disorders (ADHD)
- Bipolar disorder
- Major depression
- Obsessive compulsive disorder
Meet the Team